Liraglutide biosimilar (CinnaGen)

利拉鲁肽生物类似药 (CinnaGen)

Report date: 2023/09/25 15:42:42

Base Information

Drug NameLiraglutide biosimilar (CinnaGen)

Drug Alias Name利拉糖肽生物仿制药 (CinnaGen)利拉鲁肽生物仿制药 (CinnaGen)Melitide

ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Biosimilar

Mechanisms of ActionGlucagon-like peptide 1 receptor agonists

TargetsGlucagon-like peptide 1 receptor

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIran

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesCinnagen

China Registration ClassN/A

Active CompaniesCinnagen

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 2

Inactive IndicationsN/A

ATC CodeA10BJ02